ANG Lifesciences India Limited Overview
ANG Lifesciences India Limited is an Amritsar-headquartered micro-cap manufacturer of finished pharmaceutical formulations, built around sterile dry-powder injection vials across beta-lactam, non-beta-lactam, cephalosporin and carbapenem lines, produced at Baddi in Himachal Pradesh, India's largest formulation cluster. It sells through four channels — government and institutional tenders, third-party (contract) manufacturing, direct marketing to hospitals and doctors via stockists, and exports to Africa, the Gulf and other rest-of-world markets — and since April 2021 has owned a printing and packaging subsidiary acquired out of insolvency for backward integration. The company enjoyed a pandemic-era surge to ₹354 Cr consolidated revenue and ₹40 Cr profit in FY2022, but revenue has since contracted to ~₹93 Cr with four consecutive annual losses. FY2026 audit disclosures flagged ₹25.86 Cr of defaults to HDFC Bank, and its bank-facility rating has fallen from BBB to C. It is today a distressed, promoter-controlled turnaround candidate rather than a growth franchise.
Company's own description
The company's annual reports describe its business as the manufacturing and marketing of finished pharmaceutical formulations in the dosage form of sterile dry-powder injection vials, with dedicated areas, machinery and equipment for beta-lactam and non-beta-lactam products under GMP norms (company summary reproduced by IIFL and Kotak Neo). The FY2025 annual report, as summarised by Screener.in, places the company within the "ANG Group", described as a WHO-GMP certified consortium of pharmaceutical companies, manufacturing finished formulations in non-beta-lactam, beta-lactam, cephalosporin and carbapenem segments. The FY2023 annual report states the vision of reaching every hospital with quality critical-care products and a mission of affordable medicines globally (Annual Report FY2022-23, pp. 3–4).
Infomerics' rating rationale (Aug 2026, Sep 2025, Feb 2024) gives a broader product description: dry-powder injections, liquid injections, capsules, tablets, ointments and syrups, with the plant on Baddi–Nalagarh Road and ISO 9001:2008 certification.
Business model and revenue model
Product model (≈99% of FY2026 consolidated revenue): manufacture-and-sell of branded/generic finished formulations. Revenue is product sales; no material service, subscription or licensing income is disclosed.
Contract manufacturing: "third-party manufacturing" is cited as one of four market segments (Screener.in business summary of annual report), i.e., ANG manufactures formulations under other marketers' brands — a fee/transfer-price model embedded in product revenue.
- Printing & packaging (≈1–9% of revenue depending on year, derived): Mansa Print & Publishers produces mono-cartons, printed paper, corrugated boxes and aluminium blister foils, sold partly to ANG (inter-segment) and partly to third parties.
Value chain position
ANG sits in the formulation (finished dosage form) stage of the pharmaceutical value chain: it buys active pharmaceutical ingredients (APIs — e.g., sterile cephalosporin and carbapenem powders, typically sourced from Indian/Chinese API makers; specific suppliers not disclosed), fills them aseptically into vials, packages and distributes. The Mansa acquisition moved it one step upstream into secondary packaging, which management said represents about 15–20% of formulation product cost (company filing quoted by AL Circle, 3 Apr 2021).
Customer types and end-markets
| Channel (as described by company) | Customer type | Commercial characteristic |
|---|---|---|
| Institutional | Central/state government hospitals, procurement corporations, defence/railway/PSU hospitals (specific named buyers not disclosed) | Tender-based, price-driven, long receivable cycles |
| Third-party manufacturing | Pharma marketing companies | Volume contracts, thin margins |
| Direct marketing | Hospitals and doctors, via stockists (since 2014-15) | Branded generics, better margins, field-force dependent |
| Exports | Africa, Gulf countries, other ROW | Registration-dependent, semi-regulated markets |
| Printing & packaging (Mansa) | Pharma companies in the Baddi cluster, including ANG | Job-work/converter economics |
Source: Screener.in summary of annual report; IIFL company summary.
Independent characterisation
ANG is best understood as a sub-scale, institution-heavy sterile antibiotics filler whose economics are dominated by working capital rather than by IP or brands. Three features stand out. First, extreme volatility: revenue rose from ₹154 Cr (FY2021) to ₹354 Cr (FY2022) and then fell 74% to ₹93 Cr (FY2025), indicating that the FY2022 peak was driven by pandemic-period critical-care injectable demand rather than durable share gains (the specific products driving FY2022 are not identified in sources reviewed). Second, working-capital intensity: debtor days rose from 105 (FY2022) to 267 (FY2026) and the cash conversion cycle from 51 to 238 days (Screener.in), consistent with slow-paying institutional customers and/or stressed collections. Third, financial distress: interest consumes all operating profit, banks report defaults, and the company has stopped cooperating with its rating agency. The investable question is therefore not growth but solvency and restructuring.
Strategy
Stated strategy (themes from company disclosures)
The latest annual report and MD&A could not be retrieved directly. Themes consistently present in company-sourced material are:
-
Critical-care hospital reach — the FY2023 annual report vision centres on supplying quality critical-care products to every hospital.
-
Affordable medicines globally — the mission statement emphasises affordability and international supply.
-
Backward integration — the Mansa acquisition was framed as securing packaging supply and reducing a cost component worth 15–20% of product cost (AL Circle, Apr 2021).
-
Channel diversification across institutional, contract manufacturing, direct marketing and exports (annual report business description per Screener.in).
-
Expansion in semi-regulated export markets (Africa, Gulf, ROW).
Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)
No new business launches, partnerships, platform investments, cost programmes with quantified targets, or ESG commitments were announced on BSE in the period, based on the announcement records reviewed (ScanX; Screener.in; Business Standard). Observable actions are defensive:
Deleveraging from operating cash: ₹11 Cr operating cash flow in FY2026 directed to ₹12 Cr net financing outflow.
Capex freeze: implied net capex of ~₹0 in FY2026.
Cost containment: FY2026 operating expenses fell to ₹90 Cr from ₹94 Cr on flat revenue, lifting EBITDA from -₹1 Cr to +₹3 Cr.
Statutory dues clearance: management stated it had paid income-tax dues flagged by the FY2025 auditor and referred to ₹53.45 lakh of EPF dues (Directors' Report FY2025, IIFL reproduction).
Guidance and medium-term targets
The company has not issued public revenue, margin or debt guidance in the last 24 months, and no earnings call has been held since August 2022 (Screener.in concall list). Infomerics has repeatedly cited the company's failure to provide information since November 2023.
Products & Services
The company does not publish a public SKU-level price list in the sources reviewed, and specific brand names were not verifiable. The catalogue below is organised by segment and dosage platform, using the company's own category disclosures.
Pharmaceuticals segment — Dosage platforms
| Platform | Description / capability | Target customer | Since | Pricing model | Source |
|---|---|---|---|---|---|
| Sterile dry-powder injection vials (core) | Aseptically filled powder for reconstitution; dedicated areas and equipment for beta-lactam and non-beta-lactam lines under GMP | Hospitals, government institutions, contract clients, export | 2008-09 | Tender prices (institutional); trade prices to stockists; contract transfer prices | IIFL; Kotak Neo |
| Liquid injections | Small-volume parenterals | As above | — | — | Infomerics |
| Capsules | Oral solid | — | — | — | Infomerics |
| Tablets | Oral solid | — | — | — | Infomerics |
| Ointments | Topical | — | — | — | Infomerics |
| Syrups | Oral liquid | — | — | — | Infomerics |
Pharmaceuticals segment — Technology blocks (injectables)
| Block | What it covers | Why it matters | Source |
|---|---|---|---|
| Beta-lactam (penicillins) | Penicillin and penicillin + beta-lactamase inhibitor combinations | Regulatory requirement for segregated facilities creates a modest entry barrier | Screener.in AR summary; Groww |
| Cephalosporins | Cephalosporin dry-powder injections | High-volume hospital antibiotics; intensely tender-competed | Screener.in AR summary |
| Carbapenems | Carbapenem dry-powder injections | Higher-value reserve antibiotics for resistant infections | Screener.in AR summary; Groww |
| Non-beta-lactam | Other dry-powder injectables (see therapeutic categories) | Broadens hospital basket | Screener.in AR summary |
Therapeutic categories disclosed
Antibiotics; antivirals; antimalarials; anti-ulcer agents; carbapenems; corticosteroids; penicillins; and beta-lactamase inhibitor combinations (Groww company profile based on company disclosures). Representative molecules in these categories in the Indian injectable market (for example ceftriaxone, meropenem, piperacillin-tazobactam, pantoprazole, artesunate, methylprednisolone, acyclovir) are cited for orientation only and are not confirmed as ANG SKUs.
Printing & Packaging segment (Mansa Print & Publishers)
| Product | Description | Target customer | Source |
|---|---|---|---|
| Mono-cartons | Printed folding cartons for unit packs | ANG and Baddi-cluster pharma companies | Screener.in |
| Paper printing | Inserts, labels, leaflets | As above | Screener.in |
| Corrugation | Shipper/outer corrugated boxes | As above | Screener.in |
| Aluminium foils (blister foils) | Printed foil for blister packs | Oral solid manufacturers | Screener.in; AL Circle |
Flagship offerings, launch years, version history and list prices: not publicly disclosed.
Financial Narrative
All figures consolidated, ₹ Cr, fiscal years ending 31 March (Source: Screener.in consolidated statements compiled from BSE filings, accessed 19 Oct 2026; FY2025 and FY2026 net profit precise values from FY2026 results coverage, Whalesbook, May 2026). FY2022 is the first consolidated year (Mansa acquired 1 Apr 2021).
Income statement
Table 6.1 — Income statement (₹ Cr)
Diluted EPS equals basic EPS (no dilutive instruments disclosed). FY2023 PBT includes ₹10 Cr other income, without which the year would have been loss-making at the pre-tax level. FY2026 consolidated PBT was ₹(1,301.07) lakh (Investywise).
Dividends: Screener.in shows a 3% dividend payout for FY2022 and nil for all other years.
Margins and growth
Table 6.2 — Margins (%)
Revenue CAGR: FY2022–FY2026 (4 years) = -28.4%; FY2021–FY2026 (5 years) = -9.6% (derived from ₹154 Cr FY2021 to ₹92.89 Cr FY2026; Screener.in reports -10%).
Standalone cross-check (Infomerics, audited)
Table 6.3 — Standalone key financials (₹ Cr)
Source: Infomerics press releases, 21 Feb 2024 and 29 Sep 2025. FY2026 standalone: revenue ₹91.60 Cr, PBT ₹(5.19) Cr, PAT ₹(4.73) Cr (Whalesbook; Investywise). Infomerics also reported standalone interest coverage of 0.98x (FY2024) and -0.25x (FY2025).
Balance sheet
Table 6.4 — Balance sheet as at 31 March (₹ Cr)
Notes and gaps:
Cash & equivalents: not separately disclosed in sources reviewed; annual net cash flow has been approximately zero every year (Screener.in), indicating minimal free cash. Net debt is therefore approximated by gross borrowings (₹79 Cr at Mar 2026).
Short-term vs long-term debt split: not publicly disclosed in sources reviewed. The rated bank facilities (Infomerics, 24 Aug 2026) indicate the structure: cash credit ₹39.50 Cr (short-term, revolving), term loans ₹0.97 Cr, ₹1.94 Cr and ₹6.75 Cr (the last maturing Nov 2027), plus non-fund-based bank guarantee ₹5.00 Cr and letter of credit ₹15.00 Cr. Borrowings above the rated ₹49.16 Cr fund-based limit (~₹30 Cr at Mar 2026) likely include unsecured/promoter or other loans — composition not disclosed.
Goodwill & intangibles: not publicly disclosed.
Working capital and current ratio: not publicly disclosed in sources reviewed. Screener.in "working capital days" moved from 20 (FY2022) to 72 (FY2025) and -8 (FY2026); the negative FY2026 figure reflects stretched payables and statutory dues rather than efficiency.
Open charges: registered with MCA: ₹81.62 Cr (TheCompanyCheck). Contingent liabilities: ₹15.7 Cr (Screener.in, latest annual report).
Cash flow
Table 6.5 — Cash flow (₹ Cr)
Notes: FY2022 investing outflow of ₹44 Cr coincides with the Mansa acquisition and capacity investment. The FY2024 investing inflow of ₹20 Cr and ₹30 Cr fall in fixed assets indicate an asset sale (not detailed in sources).
Ratios
Table 6.6 — Return, leverage and efficiency ratios
Notes: ROCE for FY2022 is not reported by Screener.in (shown as 0 to preserve the chartable format; treat as not available). FY2025 debt/EBITDA is mathematically negative because EBITDA was negative — economically "not meaningful". Screener.in reports FY2026 ROE as -16% on an average-equity basis; ROIC is not publicly disclosed (ROCE is the closest proxy).
Quarterly trajectory (consolidated, ₹ Cr)
Table 6.7 — Last 13 quarters
Source: Screener.in quarterly consolidated results compiled from BSE filings. TTM to Jun 2026: sales ₹83.6 Cr, net loss ₹13.3 Cr, EPS -₹10.21.
Commentary on trends, inflections and drivers
FY2022 peak (inflection up). Revenue more than doubled to ₹354 Cr and EBITDA margin reached 19%, coinciding with exceptional pandemic-period hospital demand for injectable antibiotics, antivirals and corticosteroids. The company itself did not attribute the surge to specific products in sources reviewed, but the subsequent symmetrical collapse strongly suggests non-recurring demand rather than structural share gains. Comparable small injectable makers in Punjab show the same pattern: Kwality Pharmaceuticals' revenue fell 45% in FY2023 after a FY2022 spike (StockAnalysis), indicating an industry-wide normalisation.
FY2023–FY2025 (contraction). Revenue fell 38%, 34% and 36% in successive years. Fixed costs did not fall proportionately, so EBITDA margin compressed from 19% to -1.6%, and with ₹9–12 Cr of annual interest the company slipped into persistent pre-tax losses from FY2024. Working capital deteriorated sharply: inventory days rose from 59 to 331 and debtor days from 105 to 262, meaning that the company was carrying roughly 2.5–3 years' worth of combined inventory and receivables relative to its shrunken sales by FY2025, financed by stretching payables to 405 days.
FY2026 (stabilisation, not recovery). Revenue was flat (₹92.89 Cr) and EBITDA turned modestly positive (₹3 Cr, 2.8%), helped by a strong Q4 FY2026 (EBITDA margin 11.4%). Operating cash flow of ₹11 Cr was used to repay ₹12 Cr of financing, and borrowings fell to ₹79 Cr. However, interest (₹8 Cr) still exceeded EBITDA nearly threefold, and the auditor flagged defaults.
Q1 FY2027 (relapse). Sales fell 38% YoY to ₹15.30 Cr — the weakest quarter in the 13-quarter series — with EBITDA margin of -12.8% and net loss of ₹4.24 Cr (Business Standard / Capital Market, 15 Aug 2026), prompting the August 2026 rating downgrade to C. Equity has fallen from ₹86 Cr (FY2023) to ₹53 Cr (FY2026); at the TTM loss rate, book value would erode by roughly a quarter per year absent a capital infusion.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Business | Location |
|---|---|---|---|
ANG Lifesciences India Ltd | Listed parent | Pharmaceutical formulations | Amritsar (RO) / Baddi (plant) |
Mansa Print & Publishers Ltd (incorporated 5 Aug 2003) | Wholly owned subsidiary since 1 Apr 2021 | Printing & packaging (mono-cartons, printed paper, corrugation, aluminium blister foil) | Baddi, Himachal Pradesh |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Consolidated revenue (INR Cr) | 354 | 220 | 145 | 93 | 92.89 |
Pharmaceuticals revenue — standalone proxy (INR Cr) | 348.67 | 207.01 | 131.37 | 89.91 | 91.60 |
Printing & Packaging external revenue — derived (INR Cr) | 5.33 | 12.99 | 13.63 | 3.09 | 1.29 |
Pharmaceuticals share of revenue (%) | 98.5 | 94.1 | 90.6 | 96.7 | 98.6 |
Printing & Packaging share of revenue (%) | 1.5 | 5.9 | 9.4 | 3.3 | 1.4 |
Pharmaceuticals revenue growth YoY (%) | 126.4 | -40.6 | -36.5 | -31.6 | 1.9 |
Standalone (Pharma) net profit (INR Cr) | 39.72 | -0.66 | -8.65 | -10.34 | -4.73 |
Consolidated net profit (INR Cr) | 40.00 | -0.26 | -10.15 | -12.41 | -11.08 |
Subsidiary and consolidation effect on net profit — derived (INR Cr) | 0.28 | 0.40 | -1.50 | -2.07 | -6.35 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 354 | 220 | 145 | 93 | 92.89 |
Operating expenses (INR Cr) | 286 | 205 | 135 | 94 | 90 |
EBITDA / operating profit (INR Cr) | 68 | 15 | 10 | -1 | 3 |
Depreciation (INR Cr) | 6 | 9 | 8 | 7 | 6 |
EBIT — derived EBITDA less depreciation (INR Cr) | 62 | 6 | 2 | -8 | -3 |
Other income (INR Cr) | 1 | 10 | -1 | 2 | -1 |
Interest expense (INR Cr) | 9 | 12 | 11 | 9 | 8 |
Profit before tax (INR Cr) | 54 | 3 | -11 | -16 | -13 |
Net profit (INR Cr) | 40 | -0.26 | -10.15 | -12.41 | -11.08 |
EPS basic (INR) | 31.02 | -0.20 | -7.77 | -9.50 | -8.49 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin (%) | 19.2 | 6.8 | 6.9 | -1.6 | 2.8 |
EBIT margin — derived (%) | 17.5 | 2.7 | 1.4 | -8.6 | -3.2 |
PBT margin (%) | 15.3 | 1.4 | -7.6 | -17.2 | -14.0 |
Net margin (%) | 11.3 | -0.1 | -7.0 | -13.3 | -11.9 |
Revenue growth YoY (%) | 129.9 | -37.9 | -34.1 | -35.9 | -0.1 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total operating income (INR Cr) | 348.67 | 207.01 | 131.37 | 89.91 |
EBITDA (INR Cr) | 65.09 | 11.07 | 9.12 | -1.81 |
PAT (INR Cr) | 39.72 | -0.66 | -8.65 | -10.34 |
Total debt (INR Cr) | 60.99 | 52.75 | 55.77 | 67.80 |
Tangible net worth (INR Cr) | 83.48 | 82.81 | 73.73 | 63.12 |
EBITDA margin (%) | 18.67 | 5.35 | 6.94 | -2.01 |
Overall gearing (x) | 0.73 | 0.64 | 0.76 | 1.07 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr) | 10 | 13 | 13 | 13 | 13 |
Reserves (INR Cr) | 73 | 73 | 63 | 51 | 40 |
Total equity (INR Cr) | 83 | 86 | 76 | 64 | 53 |
Total borrowings (INR Cr) | 77 | 71 | 73 | 83 | 79 |
Other liabilities (INR Cr) | 130 | 119 | 92 | 82 | 78 |
Total assets (INR Cr) | 290 | 276 | 241 | 230 | 210 |
Net fixed assets (INR Cr) | 93 | 88 | 58 | 57 | 51 |
Other assets incl. receivables, inventory, cash (INR Cr) | 198 | 188 | 183 | 172 | 160 |
Implied trade receivables — derived from debtor days (INR Cr) | 101.8 | 83.2 | 73.1 | 66.8 | 67.9 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operating activities (INR Cr) | 25 | 26 | -9 | 0 | 11 |
Cash from investing activities (INR Cr) | -44 | -9 | 20 | -2 | 1 |
Cash from financing activities (INR Cr) | 20 | -17 | -10 | 2 | -12 |
Net cash flow (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Free cash flow as reported by Screener (INR Cr) | -17 | 16 | 9 | -4 | 11 |
Implied capex net of disposals — derived (INR Cr) | 42 | 10 | -18 | 4 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing equity — derived (%) | 48.2 | -0.3 | -13.4 | -19.4 | -20.9 |
ROA — derived (%) | 13.8 | -0.1 | -4.2 | -5.4 | -5.3 |
ROCE as reported (%) | 0 | 9 | 1 | -4 | -2 |
Debt to equity (x) | 0.93 | 0.83 | 0.96 | 1.30 | 1.49 |
Gross debt to EBITDA (x) | 1.1 | 4.7 | 7.3 | -83.0 | 26.3 |
Interest coverage EBIT/interest — derived (x) | 6.9 | 0.5 | 0.2 | -0.9 | -0.4 |
Asset turnover (x) | 1.22 | 0.80 | 0.60 | 0.40 | 0.44 |
Debtor days | 105 | 138 | 184 | 262 | 267 |
Inventory days | 59 | 118 | 183 | 331 | 288 |
Days payable | 113 | 165 | 254 | 405 | 317 |
Cash conversion cycle (days) | 51 | 91 | 113 | 189 | 238 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales (INR Cr) | 56.46 | 33.26 | 18.55 | 37.84 | 18.41 | 32.88 | 24.73 | 16.82 | 24.60 | 26.05 | 18.73 | 23.50 | 15.30 |
EBITDA (INR Cr) | 6.54 | 1.66 | -1.91 | 3.36 | -1.71 | 2.28 | -2.15 | -0.70 | 0.65 | 0.08 | -2.68 | 2.68 | -1.95 |
EBITDA margin (%) | 11.58 | 4.99 | -10.30 | 8.88 | -9.29 | 6.93 | -8.69 | -4.16 | 2.64 | 0.31 | -14.31 | 11.40 | -12.75 |
Interest (INR Cr) | 2.31 | 2.29 | 2.51 | 3.84 | 2.08 | 2.18 | 2.00 | 2.42 | 1.94 | 1.89 | 1.93 | 2.18 | 2.24 |
PBT (INR Cr) | 2.36 | -2.63 | -6.36 | -4.08 | -4.14 | -1.29 | -6.38 | -3.89 | -2.73 | -3.21 | -5.96 | -1.10 | -5.58 |
Net profit (INR Cr) | 1.75 | -2.32 | -5.93 | -3.65 | -3.07 | -2.09 | -5.19 | -2.06 | -2.01 | -2.95 | -4.75 | -1.38 | -4.24 |
EPS (INR) | 1.34 | -1.78 | -4.54 | -2.80 | -2.35 | -1.60 | -3.97 | -1.58 | -1.54 | -2.26 | -3.64 | -1.06 | -3.25 |
Region Overview
| Region | Status | Channel |
|---|---|---|
India | Core market (majority of revenue per GuruFocus) | Institutional tenders, third-party manufacturing, direct to hospitals/doctors via stockists |
Africa | Export market | Distributors / registrations |
Gulf countries | Export market | Distributors / registrations |
Other rest of world | Export market | — |
“—” = not publicly disclosed.
Share Price & Returns
| Horizon | Return | Source |
|---|---|---|
1 year | +22% | Screener.in |
3-year CAGR | -19% | Screener.in |
5-year CAGR | -36% | Screener.in |
52-week range | ₹17.6 – ₹49.7 | Screener.in |
5-year high (adjusted) | ~₹640 (during the FY2022 boom) | Sharpely (12 Aug 2026; adjusted for bonus) |
Valuation Multiples
| Multiple | ANG | Basis | Peer reference (Value Research; TTM) |
|---|---|---|---|
P/E | Not meaningful (TTM EPS -₹10.21) | Screener.in | Shilpa 70.0x; Caplin 30.1x; Pfizer 24.0x; Eris 25.6x |
P/B | ~0.93x (book ₹40.5) | Screener.in | Shilpa 7.7x; Caplin 5.5x; Pfizer 4.0x; Eris 4.1x |
EV (derived) | ~₹128 Cr (market cap ₹49.3 Cr + borrowings ₹79 Cr; cash not deducted) | Derived | — |
EV/Sales | ~1.5x on TTM sales ₹83.6 Cr | Derived | — |
EV/EBITDA | Not meaningful (TTM EBITDA ~-₹2 Cr) | Derived | — |
Long-term by Date
| Date | Long-term (₹49.16 Cr fund-based) | Short-term (₹20 Cr non-fund-based) |
|---|---|---|
4 Jun 2021 | IVR BBB- / Stable | IVR A3 |
1 Sep 2022 | IVR BBB / Stable | IVR A3+ |
28 Nov 2022 | IVR BBB- / Stable | IVR A3 |
8 Jun 2023 | IVR BB+ / Negative | IVR A4+ |
16 Nov 2023 | IVR BB / Negative | IVR A4 |
30 Nov 2023 | IVR BB / Negative / INC | IVR A4 / INC |
21 Feb 2024 | IVR BB- / Negative / INC | IVR A4 / INC |
21 Aug 2024 | IVR B+ / Negative / INC | IVR A4 / INC |
29 Sep 2025 | IVR B / Negative / INC | IVR A4 / INC |
24 Aug 2026 | IVR C / Negative / INC | IVR A4 / INC |
Debt Facilities
| Facility | Amount (INR Cr) | Maturity |
|---|---|---|
Cash credit | 39.50 | Revolving (annual renewal) |
Term loan 1 | 0.97 | July 2023 (latest maturity details not available — likely overdue/extended) |
Term loan 2 | 1.94 | August 2024 (latest maturity details not available) |
Term loan 3 | 6.75 | November 2027 |
Bank guarantee (non-fund) | 5.00 | — |
Letter of credit (non-fund) | 15.00 | — |
Analyst Conclusions
Management guidance and consensus
Management has issued no quantitative guidance and holds no earnings calls; there is no analyst consensus. The observable trajectory is: FY2026 revenue flat at ₹92.89 Cr with EBITDA of ₹3 Cr; Q1 FY2027 revenue down 38% YoY with a ₹4.24 Cr loss; TTM revenue ₹83.6 Cr and loss ₹13.3 Cr.
Bull case
-
Operating leverage on idle capacity: the same asset base produced ₹68 Cr EBITDA in FY2022; Q4 FY2026 (11.4% EBITDA margin) shows that even a modest volume recovery restores positive operating profit. Contract-manufacturing wins could swing EBITDA meaningfully on a ₹90–120 Cr revenue base.
-
Balance-sheet resolution optionality: a settlement with HDFC Bank or a promoter/strategic capital infusion would remove most of the ~₹8 Cr interest drag; at ~0.93x book and ~1.5x EV/sales, the equity is priced for distress.
-
Asset value: segregated sterile beta-lactam/cephalosporin/carbapenem capacity in Baddi is scarce and regulatory-gated; a larger player could find acquisition cheaper than greenfield construction.
Bear case
-
Default trajectory: ₹25.86 Cr already in default, rating at C, interest exceeding EBITDA, and negligible free cash — the base case risk is lender enforcement or insolvency, in which equity holders could be heavily impaired.
-
Structural uncompetitiveness: peers Kwality (₹503 Cr, ~24% EBITDA margin) and Venus (₹770 Cr, ~19%) are scaling with regulatory upgrades and R&D, while ANG shows no capex, no R&D and declining volumes.
-
Governance and transparency: absent internal auditor, rating non-cooperation, 44.9% promoter pledge, and a loss-making subsidiary with opaque economics reduce confidence that reported assets (₹68 Cr receivables, high inventory) are fully realisable.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| By ~14 Nov 2026 | Q2 FY2027 results — does revenue recover toward ₹25 Cr/quarter, and is EBITDA positive? |
| Ongoing | Any disclosure of lender action, one-time settlement, restructuring, or IBC application |
| Ongoing | Promoter pledge changes or invocation; any promoter fund infusion or preferential issue |
| Ongoing | Infomerics next review (rating at C — next step is D, i.e., default) |
| Feb 2027 | Q3 FY2027 results; receivable and inventory trends |
| May 2027 | FY2027 audited results and auditor's report (going-concern language, default status, internal audit) |
| Ongoing | Mansa Print & Publishers — impairment, divestment or closure |
| Ongoing | Revised Schedule M compliance and any regulatory inspection outcomes at Baddi |
Analyst verdict
ANG Lifesciences is a case study in how a small sterile-injectables manufacturer can be lifted by a demand shock and then left stranded when it fades. In FY2022 the company generated ₹354 Cr of consolidated revenue, a 19% EBITDA margin and ₹40 Cr of profit; four years later it reports ₹93 Cr of revenue, a 2.8% EBITDA margin, an ₹11 Cr loss, a 238-day cash conversion cycle, and an auditor's disclosure of ₹25.86 Cr in defaults to its principal lender. Its bank-facility rating has slid nine notches from BBB to C in three years, largely under "issuer not cooperating" status — itself a red flag about management transparency.
The industry is not the explanation. A same-city peer, Kwality Pharmaceuticals, suffered a similar post-pandemic revenue collapse yet doubled revenue to ₹503 Cr by FY2026 through regulatory upgrades and portfolio investment; Venus Remedies grew to ₹770 Cr with double-digit margins. ANG, by contrast, has frozen capex, discloses no R&D, and has watched its packaging subsidiary shrink to near-zero external sales while widening consolidated losses.
The equity's appeal rests on optionality: sterile capacity that is hard to replicate, a price below book value, and evidence from Q4 FY2026 that margins recover quickly with volume. But that optionality is subordinate to creditors. With interest roughly three times EBITDA, net worth falling by ₹11–13 Cr a year, and Q1 FY2027 revenue down 38%, the realistic paths are a lender-negotiated settlement backed by fresh promoter or strategic capital, or a formal insolvency process. Absent a disclosed recapitalisation plan, the risk-reward is unfavourable for minority shareholders. Our assessment is High Risk / Distressed — Avoid pending a credible debt-resolution and capital-infusion announcement; the key signals to change that view would be cured defaults, a rating upgrade off C, and two consecutive quarters of positive EBITDA above ₹2 Cr per quarter.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | On board since | Prior roles / other boards | Education | Age | Source |
|---|---|---|---|---|---|---|
Rajesh Gupta (DIN 01423407) | Founder, Managing Director (MD since 1 Oct 2016) | 14 Jun 2006 | Director of Mansa Print & Publishers, ANG Healthcare India Pvt Ltd, Les Reins Lifesciences Pvt Ltd and other promoter entities (11 active directorships); former director RN Chemicals & Pharmaceutical Pvt Ltd | Undergraduate degree, Thapar University (1993) | ~52–53 (52 per Simply Wall St, 2025) | Tofler; MarketScreener; Simply Wall St |
Saruchi Gupta (DIN 03618458) | Whole-time Director & CFO | 1 Apr 2011 | Director of Mansa Print & Publishers, Baddi Agro Pvt Ltd, ANG Innovative Products & Systems Pvt Ltd (9 active directorships) | — | — | Tofler; MarketsMojo |
Sukhpal Singh | — | 2 May 2016 | — | — | — | TheCompanyCheck |
Mrs. Chetna | Independent Director; re-appointed for a second 5-year term from 12 Oct 2026 to 11 Oct 2031 | 12 Oct 2021 | — | — | — | BSE announcement 30 Sep 2026 |
Rohit Mittal | Director (retires by rotation, i.e., non-independent); re-appointed at 2026 AGM | 11 Oct 2023 | — | — | — | TheCompanyCheck; ScanX |
Harvinder Singh Dhami | — | 27 May 2024 | — | — | — | TheCompanyCheck |
“—” = not publicly disclosed.
Directors' Remuneration
| Executive | Latest disclosed compensation | Period | Source |
|---|---|---|---|
Rajesh Gupta (MD) | Total ~₹10.8 million (~₹1.08 Cr; ~US$126k), described as above the median for Indian companies of similar size | Latest year available to Simply Wall St (circa FY2025) | Simply Wall St |
Rajesh Gupta (MD) | Remuneration approved value ₹54.00 lakh for H1 FY2023 | H1 FY2023 | BSE RPT disclosure, 25 Nov 2022 |
Independent directors | Sitting fees; amounts not publicly disclosed in sources reviewed | — | — |
Board & Management Changes
| Date | Change | Source |
|---|---|---|
11 Oct 2023 | Rohit Mittal appointed director | TheCompanyCheck |
27 May 2024 | Harvinder Singh Dhami appointed director | TheCompanyCheck |
7 Sep 2026 | Board recommends Rohit Mittal's re-appointment by rotation and Chetna's second term | ScanX |
30 Sep 2026 | AGM approves both | BSE announcement |
Governance Overview
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Promoter holding (%) | 71.14 | 70.60 | 70.60 | 70.60 | 70.60 |
Public holding (%) | 28.86 | 29.40 | 29.39 | 29.39 | 29.40 |
Number of shareholders | 4,259 | 7,163 | 6,868 | 6,508 | 5,952 |
Major Shareholders
| Holder | Stake | Notes |
|---|---|---|
Rajesh Gupta (promoter) | ~70.41% | Direct holding (MarketsMojo; Simply Wall St) |
Other promoter group (incl. Saruchi Gupta) | ~0.19% (derived) | — |
Promoter pledge/encumbrance | ~44.9% of promoter holding | Screener.in |
Foreign institutional investors | — | Screener.in shows no FII/DII category |
Domestic institutions / mutual funds | — | As above |
Retail and others | ~29.4% across ~5,666 holders | Top non-promoter holders not publicly disclosed in sources reviewed |
Competitive Landscape
Key Competitors
| Competitor | HQ | Overlap with ANG | Relative positioning | Key data (verified) |
|---|---|---|---|---|
Venus Remedies Ltd | Panchkula, Haryana | Critical-care injectables, antibiotics (incl. carbapenems), oncology; exports | Much larger, R&D-led, profitable | FY2026 revenue ₹769.60 Cr (+17.9%); PAT ₹102.79 Cr; OPM 19.1% (Capital Market, 27 May 2026) |
Kwality Pharmaceuticals Ltd | Amritsar, Punjab | Injectables, beta-lactam, general formulations; same city of origin | Rapidly scaling; EU-GMP certified plants | FY2026 revenue ₹503.08 Cr (+35.9%); PAT ₹67.35 Cr; EBITDA margin ~24% (Capital Market; FilingReader) |
Gland Pharma Ltd | Hyderabad | Sterile injectables (CDMO, regulated markets) | Global scale; different market tier | — |
Caplin Point Laboratories / Caplin Steriles | Chennai | Injectables for emerging and regulated markets | Strong in LatAm/Africa | TTM revenue ₹2,287 Cr; net margin 28.1% (Value Research peer table) |
Shilpa Medicare Ltd | Raichur, Karnataka | Injectables (oncology), CDMO | Larger, specialty | TTM revenue ₹1,682 Cr; net margin 16.2% (Value Research) |
Nectar Lifesciences Ltd | Chandigarh/Punjab | Cephalosporin APIs and formulations | Larger cephalosporin integrator | — |
Orchid Pharma Ltd | Chennai | Cephalosporin APIs/sterile | API-integrated | — |
Brooks Laboratories Ltd | Baddi, HP | Dry-powder injectables (beta-lactam, cephalosporin) | Comparable micro-cap | — |
Lyka Labs Ltd | Gujarat | Injectables | Comparable small-cap | — |
Large-cap generics (Pfizer India, Eris Lifesciences, Alkem, Aristo — hospital antibiotic brands) | Various | Branded hospital antibiotics | Dominant brand and field-force scale | Pfizer TTM revenue ₹2,570 Cr; Eris ₹3,230 Cr (Value Research) |
Packaging converters in the Baddi–Nalagarh cluster | Himachal Pradesh | Cartons, labels, foils (Mansa segment) | Fragmented, price-driven | Not compiled |
Peer Comparison FY2026
| Metric | ANG Lifesciences | Kwality Pharmaceuticals | Venus Remedies | Shilpa Medicare (TTM) |
|---|---|---|---|---|
Revenue (INR Cr) | 92.89 | 503.08 | 769.60 | 1,682.47 |
Revenue growth YoY (%) | -0.1 | 35.9 | 17.9 | — |
EBITDA / operating margin (%) | 2.8 | 24.1 | 19.1 | 28.4 |
Net margin (%) | -11.9 | 13.4 | 13.4 | 16.2 |
R&D intensity (% of revenue) | — | — | 2.4 | — |
Market cap (INR Cr) | 49.3 | — | — | 20,803 |
“—” = not publicly disclosed.



